# EyeSense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyesense

- Industry: Medical Devices & Equipment
- Headquarters: Germany
- Website: www.eyesense.com
- Total disclosed funding: $8.3M
- Latest round: Series A (Jun 1, 2005)
- Investors on record: 5

## About

Based in Germany, EyeSense GmbH operates as a developer of advanced medical technology, focusing on continuous blood glucose monitoring systems for diabetes management.EyeSense GmbH is dedicated to creating innovative solutions for diabetes management through its advanced glucose monitoring technology. The company has evolved its strategy since its inception, specifically targeting diabetes patients across Europe. Founded by Achim Muller, EyeSense has successfully completed three funding rounds, with the latest being a Series A round in November 2014, raising CHF 10.70 mn from investors including Alstertor Private Life and Novartis Venture Fund.EyeSense specializes in advanced medical technology focused on continuous blood glucose monitoring for diabetics. The company's flagship product is a state-of-the-art optical sensor that provides precise and continuous measurement of glucose concentrations in subcutaneous interstitial fluid. Designed for a wear duration of up to four weeks, the sensor minimizes waste and lowers costs while ensuring user comfort through a pain-free monitoring experience. The EyeSense system facilitates discreet, wireless real-time monitoring, with immediate alerts for blood sugar fluctuations. The technology is expected to expand its capabilities beyond glucose monitoring to include a wide array of biometric data, such as ketones and cortisol, positioning EyeSense as a versatile health monitoring solution. The company primarily targets Type 1 and Type 2 diabetes patients, with its products available in various international markets, enhancing the health management capabilities for users across Europe and potentially other regions.EyeSense generates revenue through the sale of its innovative glucose monitoring products and related services. The primary business model includes direct-to-consumer transactions, where users purchase the sensor and subscription-based services that allow for ongoing monitoring and data management through the EyeSense app. This subscription model not only provides users with real-time health insights but also includes future software updates to enhance functionality. Customers engage in a structured pricing plan that encompasses the initial purchase of the sensor, followed by monthly or annual fees for app access and software enhancements. The revenue stream is supported by a growing customer base of individuals with diabetes, aiming for improved health outcomes through reliable and sustainable monitoring solutions.The company aims to leverage recent funding to enhance its product offerings and expand into new markets. EyeSense is actively designing new products that will further diversify its health monitoring capabilities, with a focus on biometric data beyond glucose monitoring anticipated for release in the coming years. Specific regions targeted for expansion include additional markets within Europe, with plans to reach these markets by 2025. The funding raised during the Series A round in November 2014 will be utilized to support these initiatives, allowing EyeSense to develop its technology and enhance its market presence.

## Funding rounds

- Series A, Jun 1, 2005, $8.3M — Novartis Venture Fund, EQT Life Sciences, BioMed Partners, Private Life BioMed, Alstertor Private Life

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Private Life BioMed — Series A
- Alstertor Private Life — Series A